Investor Presentaiton
Q1 FY2022 Snapshot
Sales (INR mn, YoY Growth)
India,
16,362, 27%
Total
42,374, 22%
North America,
13,330, 10%
NCE Licensing
Income, 3,734
EMEA,
API,
2,459, (40%) 2,613,5%
EBITDA
INR 9,926 mn
23.4%
of sales
R&D
Growth Markets,
3,328, 10%
INR 3,737 mn
8.8%
of sales
Mr. Nilesh.D.Gupta
Managing Director
Lupin Limited
"While the quarter's profits were
bolstered by the Boehringer Ingelheim
MEK program income, despite a tough
operating environment, we see
substantial room for growth. We remain
committed to grow our US business both
with our inline products as well as ramp
up of Albuterol and Brovana, to continue
above-market growth in India, and ensure
growth in every part of the business. We
see meaningful uplift in the second half
and remain focused on our journey of
expanding margins through driving strong
double-digit revenue growth and
optimizing costs, while ensuring the
safety of our people and the highest
standards of compliance."
Important developments
Commercial
LUPIN
• Acquisition of Southern Cross Pharma in Australia,
gaining access to over 60 registered products having
sales of over AU$ 30 mn (~US$ 22 mn)
Pipeline
.
• U.S.FDA accepted the Biologics License Application for
proposed biosimilar to Neulasta® (Pegfilgrastim)
U.S.FDA approved to expand the use of SOLOSEC®
(secnidazole) to include the treatment of
trichomoniasis
Received US$50 mn as 'milestone payment' from
Boehringer Ingelheim on MEK inhibitor (novel oncology
compound) progress
• Received UK marketing authorization for Luforbec®
100/6 μg pMDI, 1st branded generic alternative to
Fostair (100/6 µg) for treatment of Asthma & COPD
• Filed 3 ANDAs, received 3 ANDA approvals in the US
Regulatory
.
Somerset facility issued warning letter by the U.S.FDA
03View entire presentation